The ACR’s RISE registry offers answers on real-world experience to researchers.
Annual Meeting Preview: Maximizing Reimbursement Under MACRA, MIPS & APMs
A session at the 2019 ACR/ARP Annual Meeting will help rheumatologists navigate current payment systems and identify resources to ensure appropriate reimbursement for complex care.
ACR Leads Coalition Opposing Cigna’s Elimination of Consultation Codes
In a letter co-signed by other Cognitive Specialty Coalition organizations, the ACR is requesting at least a one-year delay to better coordinate payer changes with recent federal initiatives.
UnitedHealthcare Delays Policy Changes Affecting Physician-Administered Treatments
Changes announced at the beginning of October have now been delayed for Actemra, Benlysta, Cimzia, Orencia and Simponi Aria, but changes to the Stelara policy remain in effect.
Not Yet Using RISE? Learn Why You Should at the Annual Meeting
Get your questions about RISE answered—and register to join—on site at the 2019 ACR/ARP Annual Meeting.
Ethics Forum: What Are Conflicts of Interest?
Results from an ethics survey presented to attendees at the 2018 ACR/ARHP Annual Meeting highlight the complexities and challenges of assessing potential conflicts of interest.
Trump Administration Proposes Changes to Healthcare Anti-Kickback Rules
(Reuters)—The Trump administration has proposed changes to federal anti-kickback provisions that restrict the kinds of patient referrals doctors can make, saying it will improve healthcare coordination and foster payments based on the quality of care. The plan will change how the U.S. Department of Health and Human Services (HHS) enforces the Physician Self Referral Law,…
New Options for Treatment-Resistant RA
Two JAK inhibitors, one recently approved by the FDA, have shown improvements in patients with active RA for whom other therapies have proved ineffective…
Mortality from Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Falling Slightly
NEW YORK (Reuters Health)—Mortality rates in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) decreased from 1999 to 2017, according to records from the Centers for Disease Control and Prevention (CDC). “The mortality attributed to several rare diseases [e.g., hypersensitivity pneumonitis] has increased in recent years,” Alexander W. Steinberg, MD, from Saint Joseph Hospital, Denver, tells…
Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases
NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 325
- Next Page »